Explore our
BioLizard Wins 2025 BioTech Breakthrough Award For “Bioinformatics Innovation of the Year”
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
Why bioinformatics workflows require experienced software engineers
Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.
Industry leader and multi-omics pioneer joins leadership team to advance AI-driven solutions
BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.
BioLizard Logs Stellar First Half of 2025: Growth, Innovation & Recognition
BioLizard’s first half of 2025 shows strong growth, AI innovation, and global recognition with new grants, leadership, and major industry awards.
BioLizard Awarded Grant from VLAIO to Advance AI-Powered Biomedical Solution for Accelerated Drug Development
VLAIO has awarded BioLizard a grant to advance its AI-driven Bio|Verse® platform. The new application will use large language models to rapidly extract and structure insights from vast biomedical datasets, empowering faster, smarter drug discovery.
What does 2025 Hold for Biopharma? Insights and opportunities.
BioLizard CEO Liesbeth Ceelen shares insights in Scrip Asks 2025 by Citeline, highlighting the growing need for robust data strategies and AI-driven insights to navigate funding, partnerships, and innovation in the evolving biopharma landscape.
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
BioLizard appoints Arjan van Manen as Commercial Director to lead global expansion and strengthen its AI-native Bio|Verse® platform. Join Arjan and CEO Liesbeth Ceelen at Biotech Showcase during JPM Week, Jan 13–15, 2025, to explore BioLizard’s latest data-driven innovations.
BioLizard has been listed as a Trends Gazelle
BioLizard named a Trends Gazelle 2025! Recognized among Belgium’s fastest-growing companies for exceptional growth, innovation, and impact in life sciences — a true testament to the power of our team and data-driven mission.
BioLizard Launches Bio|Verse® Navigator for Easy Exploration of Complex Biomedical Data
BioLizard unveils Bio|Verse® Navigator, an advanced visual analytics platform empowering scientists to explore and interpret complex biomedical data in real time. The AI-native tool accelerates discovery across biotech, pharma, and healthcare research.
Transforming veterinary research using data science, one paw at a time
In a BioVox article, BioLizard’s Volodimir Olexiouk and Steff Taelman explore how data science can bridge the gap between human and veterinary research, enabling better disease prediction, improved animal welfare, and stronger One Health outcomes.